Morning Buzz: Navidea Biopharmaceuticals, Inc (NYSEMKT:NAVB), Energy Focus, Inc. (NASDAQ:EFOI), Southwest Gas Corporation (NYSE:SWX), Akamai Technologies (NASDAQ:AKAM), La Jolla Pharmaceutical (NASDAQ:LJPC)

Navidea Biopharmaceuticals, Inc (NYSEMKT:NAVB) belongs to Healthcare sector. Its weekly performance is 5.92%. On last trading day company shares ended up $1.79. Navidea Biopharmaceuticals, Inc (NYSEMKT:NAVB) distance from 50-day simple moving average (SMA50) is 22.77%. On 2 July, Macrophage Therapeutics, Inc., a subsidiary of Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), announced that preclinical results in Kaposi’s Sarcoma (KS) demonstrated that a cytotoxic drug, doxorubicin, linked to Manocept™ was targeted to and dose-dependently taken up in CD206+ KS tumor cells and tumor associated macrophages (TAMs) and caused apoptotic death of the KS tumor cells and TAMs.

Energy Focus, Inc. (NASDAQ:EFOI) shares increased 5.59% in last trading session and ended the day at $10.57. EFOI Gross Margin is 36.00% and its return on assets is -2.70%. Energy Focus, Inc. (NASDAQ:EFOI) quarterly performance is 106.04%.

On 14 July, Southwest Gas Corporation (NYSE:SWX) shares increased 0.56% and was closed at $55.38. SWX EPS growth in last 5 year was 9.20%. Southwest Gas Corporation (NYSE:SWX) year to date (YTD) performance is -9.15%. Southwest Gas (NYSE:SWX) was upgraded by research analysts at Bank of America from a “neutral” rating to a “buy” rating in a report released on Tuesday, reports. The firm currently has a $60.00 target price on the stock, up from their previous target price of $58.00. Bank of America’s price target would indicate a potential upside of 7.95% from the company’s current price. The analysts noted that the move was a valuation call.

Akamai Technologies, Inc. (NASDAQ:AKAM) ended the last trading day at $72.29. Company weekly volatility is calculated as 1.81% and price to cash ratio as 18.10. Akamai Technologies, Inc. (NASDAQ:AKAM) showed a weekly performance of 3.11%. Akamai Technologies, Inc. (NASDAQ:AKAM) announced that the company will hold a conference call for investors on Tuesday, July 28, 2015 at 4:30 p.m. ET.

La Jolla Pharmaceutical Co. (NASDAQ:LJPC) shares increased 2.11% in last trading session and ended the day at $33.33. LJPC return on assets is -65.20%. La Jolla Pharmaceutical Co. (NASDAQ:LJPC) quarterly performance is 74.59%. On 1st July, La Jolla Pharmaceutical Company (NASDAQ: LJPC) announced that Lakhmir “Mink” S. Chawla, M.D., the Company’s Chief Medical Officer, received the International Vicenza Award for Critical Care Nephrology at the 33rd Course on Critical Care Nephrology in June 2015.

Leave a Reply

Your email address will not be published. Required fields are marked *